AAG
GILD icon

Accordant Advisory Group’s Gilead Sciences GILD Stock Holding History

Accordant Advisory Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$122K Buy
875
+525
+150% +$73.5K 0.08% 56
2025
Q4 		$43K Buy
+350
New +$42.5K 0.03% 85
2024
Q3 		– Sell
-200
Closed -$13.7K – 152
2024
Q2 		$13.7K Buy
+200
New +$13.3K 0.01% 115

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Accordant Advisory Group's GILD Position: Q1 2026 in Review

Accordant Advisory Group increased its Gilead Sciences (GILD) stake by 150% in Q1 2026, buying an estimated $73.5K and bringing the position to 875 shares worth $122K. The position accounts for 0.08% of the portfolio, ranked #56.

Accordant Advisory Group first reported a position in GILD in Q2 2024 and has held it in 3 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Accordant Advisory Group held 875 shares of Gilead Sciences worth $122K as of Q1 2026.
  • Accordant Advisory Group bought 525 Gilead Sciences shares in Q1 2026, an estimated $73.5K.
  • Gilead Sciences made up 0.08% of Accordant Advisory Group's portfolio in Q1 2026, its #56 holding.
  • Accordant Advisory Group first reported a position in Gilead Sciences in Q2 2024 and has held it in 3 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Accordant Advisory Group's 13F filing for Q1 2026, filed 11 May 2026.